Durvalumab extends survival in small cell lung cancer while raising critical cost-effectiveness concerns.
Researchers at the Sylvester Comprehensive Cancer Center (FL, USA) have unveiled findings from the ADRIATIC clinical trial, showing that durvalumab, an immune checkpoint inhibitor, significantly improves survival for patients with limited-stage small cell lung cancer (LS-SCLC). Led by Chinmay Jani and published in JCO Global Oncology, the study underscores durvalumab’s potential to advance LS-SCLC treatment. However, the high cost of the therapy raises concerns about accessibility and sustainability.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer, accounting for 15% of all cases. Despite decades of research, treatment options have remained largely unchanged, relying on…